Jellatech, Inc.

Jellatech, Inc. is a biotechnology firm focused on producing bio-identical collagen through advanced cellular agriculture and synthetic biology, revolutionizing the sourcing of collagen for multiple industries. Founded in 2020 and headquartered in Raleigh, US, Jellatech specializes in producing lab-grown human collagen. The company recently raised USD 3.

5 mn in Seed funding on August 22, 2023, led by byFounders, with participation from several other investors. CEO and founder Stephanie Michelsen has a background in biotechnology and has shown a commitment to advancing sustainable protein solutions. To date, Jellatech has completed 2 funding deals, raising a total of USD 3. 5 mn.

Jellatech specializes in the production of bio-identical collagen using advanced cellular agriculture and synthetic biology techniques. Their core offering is lab-grown human collagen, specifically triple helix collagen type I, cultivated through a unique cell-based process initiated by a one-time 3mm skin biopsy. This process eliminates reliance on animal-derived sources, addressing ethical and environmental concerns while ensuring bio-identical, highly functional collagen. Jellatech's products serve various industries, including biomedical, pharmaceutical, beauty and personal care, and food and beverage sectors, primarily targeting clients in North America and Europe who prioritize sustainability and advanced biotechnology applications.

Jellatech engages in B2B transactions, providing bio-identical collagen products to multiple sectors, including healthcare, beauty, and food industries. Their clientele includes pharmaceutical companies, cosmetic brands, and food manufacturers seeking high-quality, animal-free collagen solutions. The company's sales strategy typically involves direct agreements and partnerships, enabling clients to source customized collagen for specific applications. Pricing plans for their products are tailored to the client's requirements based on volume and application, reinforcing Jellatech's position in the sustainable protein market.

Following the recent Seed funding of USD 3. 5 mn, Jellatech intends to focus on advancing its research and development, scaling up cellular agriculture operations, and expanding its team. The funding will support the commercialization of their proteins and the design and launch of new products aimed at enhancing their portfolio. Furthermore, Jellatech plans to expand into additional markets, particularly targeting regions within Asia and South America by mid-2024, to grow its footprint and client base.